Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 39

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 39
---
 registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the
Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities
with respect to the common shares for the applicable restricted period, as defined in Regulation M, prior to the commencement of the
distribution. In addition, the selling shareholders will be subject to applicable provisions of the Exchange Act and the rules and regulations
thereunder, including Regulation M, which may limit the timing of purchases and sales of the common shares by the selling shareholders
or any other person. We will make copies of this prospectus available to the selling shareholders and have informed them of the need
to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under
the Securities Act).

<div align='center'>EXPENSES OF THIS OFFERING</div>

Set forth below is an itemization of the total
expenses, excluding placement agent discounts, expected to be incurred in connection with the offer and sale of the securities offered
by us. With the exception of the SEC registration fee, all amounts are estimates:

| SEC registration fee         |     | $ |    315 |
| Legal fees and expenses      |     |   | 25,000 |
| Accounting fees and expenses |     |   |  5,000 |
| Miscellaneous                |     |   |  5,000 |
| Total                        |     | $ | 35,315 |

<div align='center'>LEGAL MATTERS</div>

The validity of the issuance of our Common Shares
offered in this prospectus and certain other matters of Canadian law will be passed upon for us by Daniel N. Bloch. Certain matters of
U.S. federal law will be passed upon for us by Greenberg Traurig, P.A., Tel Aviv, Israel. Certain legal matters in connection with this
offering will be passed upon for the placement agent by Kaufman & Canoles, P.C., Richmond, Virginia with respect to U.S. federal
law.

<div align='center'>26

EXPERTS</div>

The financial statements of Clearmind Medicine
Inc. as of October 31, 2024 and 2023 and for the years then ended, as included in this prospectus, have been audited by Brightman Almagor
Zohar & Co., a firm in the Deloitte global network, an independent registered